Claro Advisors LLC Makes New Investment in Illumina, Inc. (NASDAQ:ILMN)

Claro Advisors LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,232 shares of the life sciences company’s stock, valued at approximately $291,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new position in Illumina in the 2nd quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV raised its position in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Illumina during the 2nd quarter valued at approximately $61,000. Finally, Mizuho Securities Co. Ltd. purchased a new stake in shares of Illumina in the 2nd quarter valued at $63,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ILMN. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday, November 12th. Piper Sandler decreased their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Canaccord Genuity Group raised their target price on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Finally, Leerink Partners boosted their price target on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Stock Performance

NASDAQ ILMN opened at $130.74 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1-year low of $93.39 and a 1-year high of $156.66. The company has a market cap of $20.74 billion, a PE ratio of -13.13 and a beta of 1.13. The stock’s 50 day simple moving average is $139.82 and its 200-day simple moving average is $124.35.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the firm posted $0.33 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.